These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26242620)

  • 1. Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles.
    Chen L; She X; Wang T; He L; Shigdar S; Duan W; Kong L
    Nanoscale; 2015 Sep; 7(33):14080-92. PubMed ID: 26242620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabrication of high specificity hollow mesoporous silica nanoparticles assisted by Eudragit for targeted drug delivery.
    She X; Chen L; Velleman L; Li C; Zhu H; He C; Wang T; Shigdar S; Duan W; Kong L
    J Colloid Interface Sci; 2015 May; 445():151-160. PubMed ID: 25617610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
    Shao M; Chang C; Liu Z; Chen K; Zhou Y; Zheng G; Huang Z; Xu H; Xu P; Lu B
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110427. PubMed ID: 31408782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hollow mesoporous silica nanoparticles facilitated drug delivery via cascade pH stimuli in tumor microenvironment for tumor therapy.
    Liu J; Luo Z; Zhang J; Luo T; Zhou J; Zhao X; Cai K
    Biomaterials; 2016 Mar; 83():51-65. PubMed ID: 26773665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity.
    Luo Z; Hu Y; Cai K; Ding X; Zhang Q; Li M; Ma X; Zhang B; Zeng Y; Li P; Li J; Liu J; Zhao Y
    Biomaterials; 2014 Sep; 35(27):7951-62. PubMed ID: 24930850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
    Gao Y; Chen Y; Ji X; He X; Yin Q; Zhang Z; Shi J; Li Y
    ACS Nano; 2011 Dec; 5(12):9788-98. PubMed ID: 22070571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shape-Controlled Hollow Mesoporous Silica Nanoparticles with Multifunctional Capping for In Vitro Cancer Treatment.
    Geng H; Chen W; Xu ZP; Qian G; An J; Zhang H
    Chemistry; 2017 Aug; 23(45):10878-10885. PubMed ID: 28580592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer-Coated Hollow Mesoporous Silica Nanoparticles for Triple-Responsive Drug Delivery.
    Zhang Y; Ang CY; Li M; Tan SY; Qu Q; Luo Z; Zhao Y
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18179-87. PubMed ID: 26221866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
    Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
    Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted H
    Deng Z; Tang M; Zhao L; Long Y; Wen Z; Cheng Y; Zheng H
    Colloids Surf B Biointerfaces; 2017 Dec; 160():207-214. PubMed ID: 28934664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
    Li T; Geng T; Md A; Banerjee P; Wang B
    Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
    Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
    Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hierarchically mesoporous silica nanoparticles: extraction, amino-functionalization, and their multipurpose potentials.
    Du X; He J
    Langmuir; 2011 Mar; 27(6):2972-9. PubMed ID: 21332153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
    Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
    Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
    [No Abstract]   [Full Text] [Related]  

  • 16. Polymeric Prodrug Grafted Hollow Mesoporous Silica Nanoparticles Encapsulating Near-Infrared Absorbing Dye for Potent Combined Photothermal-Chemotherapy.
    Zhang Y; Ang CY; Li M; Tan SY; Qu Q; Zhao Y
    ACS Appl Mater Interfaces; 2016 Mar; 8(11):6869-79. PubMed ID: 26937591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coordination-Accelerated "Iron Extraction" Enables Fast Biodegradation of Mesoporous Silica-Based Hollow Nanoparticles.
    Wang L; Huo M; Chen Y; Shi J
    Adv Healthc Mater; 2017 Nov; 6(22):. PubMed ID: 28941142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.
    Chai J; Dong W; Xie C; Wang L; Han DL; Wang S; Guo HL; Zhang ZL
    IUBMB Life; 2015 Mar; 67(3):191-201. PubMed ID: 25873402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino Acid-functionalized hollow mesoporous silica nanospheres as efficient biocompatible drug carriers for anticancer applications.
    Ezzati N; Mahjoub AR; Abolhosseini Shahrnoy A; Syrgiannis Z
    Int J Pharm; 2019 Dec; 572():118709. PubMed ID: 31629730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.
    Ke Y; Xiang C
    Int J Nanomedicine; 2018; 13():8339-8354. PubMed ID: 30584304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.